Evaluation of the Blood-Brain Barrier Transport, Population Pharmacokinetics, and Brain Distribution of Benztropine Analogs and Cocaine Using in Vitro and in Vivo Techniques
Authors:
- Jianjing CaoJCJianjing Cao
- Amy Hauck NewmanANAmy Hauck Newman
- Huanling GaoHGHuanling Gao
- Natalie D. EddingtonNENatalie D. Eddington
- 1 November 2003
- journal article
- research article
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 307 (2) , 801-808
Abstract
The N-substituted 3α-[bis(4′-fluorophenyl)methoxy]tropanes (AHN 2-003, AHN 1-055, AHN 2-005, and JHW 007) bind with high affinity to the dopamine transporter and inhibit dopamine uptake more potently than cocaine, but they demonstrate behavioral profiles in animal models of psychostimulant abuse that are unlike that of cocaine. The objective of this study was to characterize the in vitro permeability, brain distribution, and pharmacokinetics of the benztropine (BZT) analogs. Transport studies of cocaine and the BZT analogs (10-4 M) were conducted across bovine brain microvessel endothelial cells. Male Sprague-Dawley rats (∼300 g) were administered BZT analogs (10 mg/kg) or cocaine (5 mg/kg) via the tail vein. Blood and brain samples were collected over 36 h and assayed using UV-high-performance liquid chromatography. Transport of both AHN 1-055 (2.15 × 10-4 cm/s) and JHW 007 (2.83 × 10-4 cm/s) was higher (p < 0.05) than that of cocaine (1.63 × 10-4 cm/s). The volume of distribution (12.3-30.5 l/kg) of the analogs was significantly higher than cocaine (0.9 l/kg). The BZT analogs displayed a ≥8-fold higher elimination half-life (4.12-16.49 h) compared with cocaine (0.49 h). The brain-to-plasma partition coefficients were at least two-fold higher for the BZTs versus cocaine, except for AHN 2-003. The BZT analogs are highly permeable across the blood-brain barrier and possess a pharmacokinetic profile different from that of cocaine. These characteristics, in addition to their distinctive behavioral profiles, suggest that the BZT analogs may be promising candidates for the treatment of cocaine abuse.Keywords
This publication has 38 references indexed in Scilit:
- Effect of P-Glycoprotein on the Pharmacokinetics and Tissue Distribution of Enaminone Anticonvulsants: Analysis by Population and Physiological ApproachesThe Journal of Pharmacology and Experimental Therapeutics, 2002
- Highly Selective Chiral N-Substituted 3α-[Bis(4‘-fluorophenyl)methoxy]tropane Analogues for the Dopamine Transporter: Synthesis and Comparative Molecular Field AnalysisJournal of Medicinal Chemistry, 2000
- Pharmacotherapies for Treatment of Cocaine Abuse: Preclinical AspectsJournal of Medicinal Chemistry, 1999
- BIOCHEMICAL, CELLULAR, AND PHARMACOLOGICAL ASPECTS OF THE MULTIDRUG TRANSPORTERAnnual Review of Pharmacology and Toxicology, 1999
- Availability of PSC833, a substrate and inhibitor of P-glycoproteins, in various concentrations of serumJNCI: Journal of the National Cancer Institute, 1998
- Novel N-Substituted 3α-[Bis(4‘-fluorophenyl)methoxy]tropane Analogues: Selective Ligands for the Dopamine TransporterJournal of Medicinal Chemistry, 1997
- Pharmacokinetic and Pharmacodynamic Principles of Illicit Drug Use and Treatment of Illicit Drug UsersClinical Pharmacokinetics, 1997
- Use of rhodamine 123 to examine the functional activity of P-glycoprotein in primary cultured brain microvessel endothelial cell monolayersLife Sciences, 1996
- Addictive Drugs and Brain Stimulation RewardAnnual Review of Neuroscience, 1996
- A Tolerance Study of Single and Multiple Dosing of the Selective Dopamine Uptake Inhibitor GBR 12909 in Healthy SubjectsInternational Clinical Psychopharmacology, 1990